The pharmaceutical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s demonstrating significant efficacy in clinical trials for addressing obesity. Unlike some existing weight loss treatments, retatrutide appears to offer a more substantial re